BridgeBio Pharma Announces Positive Topline Results From Phase 3 ATTRibute-CM Study

Monday, July 17, 2023 1 min read

Key Takeaway: BridgeBio Pharma Announces Positive Topline Results From Phase 3 ATTRibute-CM Study

Full Press Release Details

BridgeBio Pharma Announces Positive Topline Results From Phase 3 ATTRibute-CM Study.